Shares of Sun Pharma rose as much as 2.4% in intra-day trade on Wednesday, while those of Ranbaxy jumped 2.1%. Photo: Hemant Mishra/Mint Mumbai: Sun Pharmaceutical Industries Ltd, India's most valuable drug maker, has completed the $3.2 billion ... Livemint.com, 2 days ago
Angel Broking remains neutral on 'Sun Pharma' - MyIris, 3 days ago
Sun Pharma And Ranbaxy: An Ideal Pharma Marriage? - Investopedia, 4 weeks ago
Dilip Sanghvi led Sun Pharmaceutical Industries is acquiring GlaxoSmithKline's Australian opiates business. The financial details of the deal remain undisclosed. The buy consists of two manufacturing sites, one each in Latrobe (Tasmania) and Port ...Deal Curry, 3 weeks ago
MUMBAI: Dilip Shantilal Shanghvi, the world's richest pharma tycoon and Sun Pharma managing director, is increasingly expanding his business empire into new and diverse areas, making big investments in areas such as renewable energy and payment ...Economic Times, 1 month ago
Sun Pharma dismisses buzz; Suzlon up over three per cent Digbijay Mishra & Shreya Jai | New Delhi February 3, 2015 Last Updated at 00:49 IST Shares of Suzlon rose over three per cent today on speculation that Dilip Shanghvi of Sun Pharmaceuticals ...Business Standard India, 1 month ago
Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'
A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive ...Morningstar.com, 3 weeks ago The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts Pharmacy Choice, 1 month ago The Generic Drugs Market: 2015 2030 - Opportunities, Challenges, Strategies & Forecasts Research and Markets, 1 month ago
ets are expected to open in the red tracking the SGX Nifty and weak global cues. US markets closed sharply lower led by a sell-off in technology and biotech stocks. The Commerce Department also released a report showing an unexpected drop in ...Stock Markets Review, 2 days ago
MUMBAI: Following the successful closure of the $3.2 billion merger with troubled drug maker Ranbaxy, Dilip Shanghvi-led Sun Pharma said on Wednesday that the company is initiating the integration of the business, which will make the combined entity ...Times of India, 2 days ago
Summit Corporation plc Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT APPOINTS MR DAVID WURZER AS NON-EXECUTIVE DIRECTOR Oxford, UK, 23 February 2015 - Summit Therapeutics plc (AIM: SUMM), the drug discovery and development ...4 Traders, 2 weeks ago Summit Therapeutics Appoints Mr David Wurzer as a Non-Executive Director EuroInvestor, 1 month ago Summit Therapeutics plc Summit Therapeutics Appoints Mr David Wurzer As A Non-Executive Director ADVFN UK, 1 month ago IP : Summit Therapeutics plc - Summit Therapeutics Appoints Mr David Wurzer 4 Traders, 1 month ago
More from: , FirstWord Pharma...and 3 other sources
The second richest person in India, the seventh richest self-made billionaire in Asia and the richest person in the healthcare industry with a net worth of approximately US$18 billion -- all these adjectives can be used to describe Mr. Dilip ...Investopedia, 2 months ago
on your WebpageAdd Widget >Get your members hooked!